Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada

SUMMARY: This study evaluated the cost-effectiveness of 1 year of romosozumab followed by alendronate versus oral bisphosphonates alone in women with postmenopausal osteoporosis at very high risk for fracture in Canada. Results showed that romosozumab sequenced to alendronate is a cost-effective tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Goeree, Ron, Burke, Natasha, Jobin, Manon, Brown, Jacques P., Lawrence, Donna, Stollenwerk, Björn, Willems, Damon, Johnson, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042964/
https://www.ncbi.nlm.nih.gov/pubmed/35471711
http://dx.doi.org/10.1007/s11657-022-01106-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042964/
https://www.ncbi.nlm.nih.gov/pubmed/35471711
http://dx.doi.org/10.1007/s11657-022-01106-9

Ejemplares similares